CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 12 enrolled
Drug / intervention
Suvorexant 10 mg +2 moredrug
Likely dose
Suvorexant 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03312517
NCT03312517Phase 4Completed
CompareCT.gov

A Phase IV 3-Way Double-blind, Randomized, Crossover Study to Compare the Awakening Threshold Effects (Responsivity) of Belsomra 10 mg and 20 mg to Placebo in Non-elderly Insomniacs

Henry Ford Health System·interventional·Posted Oct 17, 2017·Updated Nov 1, 2019

In Brief

A Phase 4 clinical trial evaluating Suvorexant 10 mg, Suvorexant 20 mg, and 1 other intervention for Insomnia. Completed, enrolled 12 participants across 1 site.

Detailed Summary

Phase IV 3-Way Double-blind, Randomized, Crossover Study to Compare the Awakening Threshold Effects (responsivity) of Belsomra 10 mg and 20 mg to Placebo in non-elderly Insomniacs

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInsomnia
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
201820192020202120222023202420252026
First PostedOct 17, 2017
Enrollment StartApr 15, 2018
Primary CompletionOct 25, 2018
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 8.7 years ago

Interventions

Suvorexant 10 mgdrug

Subject will receive suvorexant 10mg

Suvorexant 20 mgdrug

Subject will receive suvorexant 20mg

Placebo oral capsuledrug

Subject will receive placebo.